Leadership

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

<p>Executive Summary</p> <p>An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.</p>

<p>Executive Summary</p> <p>An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.</p>

​​​<p>Executive Summary​​ </p> ​​<br> <p>An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.</p>

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

​​​<p>Executive Summary​​ </p> ​​<br> <p>An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.</p>

​​​<p>Executive Summary​​ </p> ​​<br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>

This week, the FDA announced a new head of its device evaluation office; synthetic genomics firm Constructive Bio landed $58m in funding; and Natera got a permanent injuction against NeoGenomics Labs' RaDaR assay.

Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.

John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.  

This HBW Insight series profiles regulatory affairs specialists working in or supporting the consumer health and beauty product industries. In this installment, we speak to Kenvue's Kevin Whelan.

Recent moves in the industry include C-suite shuffle at Perspective Therapeutics and Bausch Health, plus Oculis Holding gets a new CDO and Tiziana Life Sciences gets a new CEO.

The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.

The beauty giant expects organic sales growth for fiscal 2025 to range between -1% and 2%, falling well short of analyst consensus of 7.2%, reflecting the firm’s overexposure in China and Asia travel retail. A new CEO is incoming with Fabrizio Freda set to step down in June 2025.

A round-up of the latest global health and wellness moves: Nestlé and Dr Reddy's name JV head; Be-sup hires comms and regulatory director; Ascendis Health appoints interim CFO.

Former FDA device center head Jeffrey Shuren is facing conflict of interest claims for not recusing himself from regulatory decisions involving clients of his wife’s legal firm. Critics call for an investigation and stricter ethics compliance.

A change in leadership of the US FDA device center is taking place with an eye towards stability in the longer term, but the upcoming elections could lead to more disruptive personnel changes.

The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.

This HBW Insight series profiles regulatory affairs specialists working in or supporting the consumer health and beauty product industries. In this installment, we speak to CHPA’s Mike Bailey, senior vice president of regulatory and scientific affairs; and regulatory and scientific affairs VPs Marcia Howard and Jay Sirois.

A change in leadership of the US FDA device center is taking place with an eye towards stability in the longer term, but the upcoming elections could lead to more disruptive personnel changes.